Lundbeck Says It Won't Need a Big Buy After Trial Failure
- Drugmaker has lost $4 billion in market value since Thursday
- Treatment once seen as potential blockbuster might now be dead
This article is for subscribers only.
H. Lundbeck A/S has an early answer for those wondering how it will ever plug the future sales hole that emerged when its once-promising schizophrenia drug failed a key trial.
“We do not feel pressured into doing things that we don’t think are good business deals,” Anders Pedersen, executive vice president of research and development for the Danish company, said in a phone interview Friday. “This is not a situation where we are forced into a buying situation.”